Big Data Is Remaking Big Pharma

GlaxoSmithKline recently announced a radical change in R&D spending. The British drug giant will refocus on data analytics, and the link between the immune system and human disease. It is harbinger of things to come. It is also a big opportunity for investors. GSK is trying to catch bigger trends.